At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 157 enrolled
Drug / intervention
Beta-blocker monotherapy +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
In Brief
A Phase 4 clinical trial evaluating Beta-blocker monotherapy and Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution for Open Angle Glaucoma and Ocular Hypertension. Completed, enrolled 157 participants.
Detailed Summary
The purpose of this study is to demonstrate superior intraocular pressure (IOP) control with travoprost 0.004% / timolol 0.5% compared to beta-blocker monotherapy in participants with open-angle glaucoma or ocular hypertension.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpen Angle Glaucoma, Ocular Hypertension
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedDec 2013
Primary CompletionMay 2015
TodayJul 2026
First PostedDec 6, 2013
Enrollment StartDec 1, 2013
Primary CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.6 years ago
Interventions
Beta-blocker monotherapydrug
Per participant's current prescribed therapy
Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solutiondrug